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Blood Pressure and Arterial Stiffness in Kenyan Adolescents With
a+Thalassemia
Anthony O. Etyang, MBChB, MMed, MSc; Christopher Khayeka-Wandabwa, MSc; Sailoki Kapesa, Dip Clin Med & Surg; Esther Muthumbi,
MBChB, MSc; Emily Odipo, BSc; Marylene Wamukoya, MPH; Nicholas Ngomi, MPH; Tilahun Haregu, PhD; Catherine Kyobutungi, MBChB,
MSc, PhD; Metrine Tendwa, DLT; Johnstone Makale, DLT; Alex Macharia, MSc; J. Kennedy Cruickshank, MBChB, MD, FRCP; Liam Smeeth,
PhD, FRCGP, FMedSci; J. Anthony G. Scott, FRCP; Thomas N. Williams, PhD, FRCPCH
Background-—Recent studies have discovered that a-globin is expressed in blood vessel walls where it plays a role in regulating
vascular tone. We tested the hypothesis that blood pressure (BP) might differ between normal individuals and those with
a+thalassemia, in whom the production of a-globin is reduced.
Methods and Results-—The study was conducted in Nairobi, Kenya, among 938 adolescents aged 11 to 17 years. Twenty-four-
hour ambulatory BP monitoring and arterial stiffness measurements were performed using an arteriograph device. We genotyped
for a+thalassemia by polymerase chain reaction. Complete data for analysis were available for 623 subjects; 223 (36%) were
heterozygous (a/aa) and 47 (8%) were homozygous (a/a) for a+thalassemia whereas the remaining 353 (55%) were normal
(aa/aa). Mean 24-hour systolic BP SD was 11812 mm Hg in aa/aa, 11711 mm Hg in a/aa, and 11811 mm Hg in
a/a subjects, respectively. Mean 24-hour diastolic BP SD in these groups was 648, 637, and 658 mm Hg,
respectively. Mean pulse wave velocity (PWV)SD was 70.8, 70.8, and 70.7 ms1, respectively. No differences were
observed in PWV and any of the 24-hour ambulatory BP monitoring-derived measures between those with and without
a+thalassemia.
Conclusions-—These data suggest that the presence of a+thalassemia does not affect BP and/or arterial stiffness in Kenyan
adolescents. ( J Am Heart Assoc. 2017;6: e005613. DOI: 10.1161/JAHA.117.005613.)
Key Words: adolescence • ambulatory blood pressure monitoring • a+thalassemia
T he thalassemias, in which there is disordered or absentproduction of the a- or b-globin chains that make up
normal hemoglobin, are the most common monogenic
disorders of humans.1 The geographical distribution of
a+thalassemia, in which there is deletion of 1 or more of
the HBA genes that encode a-globin (Hba) production, closely
mirrors that of malaria transmission,2 and it has been
demonstrated that these deletions confer protection against
both severe and nonsevere malaria.2–5
Although it has long been believed that Hba expression is
limited to red blood cells, it has recently been demonstrated
that Hba is also expressed in mouse endothelial cells where it
plays a role in nitric oxide (NO) signaling, inﬂuencing vascular
smooth muscle tone in resistance arteries.6,7 A macromolec-
ular complex formed by Hba and endothelial nitric oxide
synthase (eNOS), regulates NO signaling at myoendothelial
junctions.8 Disruption of this complex lowers blood pressure
(BP) in both normotensive and hypertensive mice.8 It has also
been shown that resistance arteries from mice lacking 2 of
the 4 a-globin genes (a2/a2) have reduced contractility
posttreatment with the vasoconstrictor, phenylephrine.9 Indi-
viduals with a+thalassemia have been shown to have higher
microvasculature tortuosity.10 From the foregoing, it could be
expected that individuals with a+thalassemia might have
lower BP compared with those with normal hemoglobin.
However, the few studies conducted in humans have yielded
inconsistent results. Whereas 1 review11 suggested that
a+thalassemic individuals have moderate hypotension, other
investigators have found elevated BPs in subjects with this
condition.12,13 These studies were limited by small sample
sizes and the failure to use 24-hour ambulatory blood
From the KEMRI-Wellcome Trust Research Program, Kiliﬁ, Kenya (A.O.E., S.K.,
E.M., E.O., M.T., J.M., A.M., J.A.G.S., T.N.W.); London School of Hygiene and
Tropical Medicine, London, United Kingdom (A.O.E., L.S., J.A.G.S.); African
Population and Health Research Centre, Nairobi, Kenya (C.K.-W., M.W., N.N.,
T.H., C.K.); King’s College, London, United Kingdom (J.K.C.); Imperial College,
London, United Kingdom (T.N.W.).
Correspondence to: Anthony O. Etyang, MBChB, MMed, MSc, KEMRI-
Wellcome Trust Research Program, Department of Epidemiology and Demog-
raphy, PO Box 230, Kiliﬁ, 80108 Kenya. E-mail: aetyang@kemri-wellcome.org
Received January 18, 2017; accepted March 1, 2017.
ª 2017 The Authors. Published on behalf of the American Heart Association,
Inc., by Wiley. This is an open access article under the terms of the Creative
Commons Attribution License, which permits use, distribution and reproduc-
tion in any medium, provided the original work is properly cited.
DOI: 10.1161/JAHA.117.005613 Journal of the American Heart Association 1
ORIGINAL RESEARCH
 by guest on M
arch 5, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
pressure monitoring (ABPM) to measure BP. It is known that
1-off ofﬁce/clinic BP measurements can be inﬂuenced by a
variety of environmental and psychological factors,14 limita-
tions that are overcome by use of ABPM, which is considered
the reference standard for BP measurement.14,15
If arterial stiffness and/or BP are inﬂuenced by Hba
genotype, this would be an important step that could aid the
development of compounds either mimicking or antagonizing
Hba as potential therapies for hypertension. In the current
study, we have tested the hypothesis that 24-hour BP and
arterial stiffness is different in subjects with a+thalassemia
than in healthy individuals.
Methods
This population-based study was a cross-sectional sample of
residents of the Nairobi Urban Health and Demographic
Surveillance System (NUHDSS)16 in Kenya and was conducted
between December 2015 and June 2016. Nairobi, the capital
city of Kenya, was chosen for this study for 2 reasons. First,
Nairobi is located at a high altitude (1800 m above sea level),
and there is no evidence of malaria transmission.17 This made it
possible to study the effect of a+thalassemia on BP uncon-
founded by the presence of malaria, which could potentially
inﬂuence BP18 and which a+thalassemia protects against.
Second, the population of Nairobi is composed of ethnic groups
originating from all parts of the country, including those whose
ancestral lands were endemic for malaria (eg, Luhya, Luo, Teso,
and Mijikenda), in whom the frequency of a+thalassemia is
signiﬁcantly higher.2 In order to increase our efﬁciency in
recruiting participants with a+thalassemia, we limited our
recruitment to those who identiﬁed themselves as genetically
derived from any of these ethnic groups.
The NUHDSS conducts population-wide censuses within
the study area 4 times each year.16 Using NUHDSS data, we
selected all children currently aged 11 to 17 years who had a
continuous record of residence within the study area since
birth. Continuous residency was a requirement in order to
minimize potential exposure to malaria as a result of
migration. Trained staff visited all subjects who had been
selected to participate in the study at their homes. Parents of
the children were then asked to bring them to the nearer of 2
study clinics within the area to undergo study procedures. Up
to 3 attempts were made at ﬁnding a selected subject before
concluding that they could not be found. Subjects who failed
to come to the clinic within 3 months of being invited were
considered to have declined to participate in the study.
Recruited subjects ﬁrst underwent an interview where they
answered questions about their past medical history and their
socioeconomic status based on the multidimensional poverty
index.19 Weight and height were measured using a validated
SECA 874 weighing machine and a portable stadiometer
(SECA 213), respectively. Mid-upper-arm circumference
(MUAC) was measured in a standardized manner using TALC
MUAC tapes. We then took a screening BP measurement
using a validated Omron M10-IT sphygmomanometer. An
appropriately sized cuff was placed on the nondominant arm
after the subject had been seated for at least 5 minutes.
Three BP measurements were taken over a 5-minute period,
and the mean of the last 2 measurements was recorded as
the screening BP value. All participants were subsequently
ﬁtted with a validated Arteriograph24 device for 24-hour
ABPM as well as pulse wave velocity (PWV) determination.20
These devices were programmed to take measurements every
20 minutes from 6:00 AM to 10:00 PM and every 40 minutes
from 10:00 PM to 6:00 AM.
Because there are no published criteria for acceptable ABPM
data in children, we used guidelines for completeness of ABPM
data in adults from the International Database of Ambulatory
blood pressure in relation to Cardiovascular Outcomes (IDACO)
study.21 Speciﬁcally, ABPM data were considered of acceptable
quality if they included a minimum 10 daytime and minimum 5
nighttime readings, where daytime was deﬁned as 10:00 AM to
10:00 PM and nighttime as 12:00 AM to 6:00 AM.21 The same
time periods were used to determine average daytime and
nighttime BPs and evaluate dipping status. Time weighting was
applied in calculating average BP values for all time periods.22
We deﬁned screen positives for hypertension as individuals
whose mean of the last 2 clinic BP measurements was above
the 95th percentile for their age, sex, and height.15 Conﬁrmed
hypertensives were those whose 24 hours systolic (SBP)
and/or diastolic BP (DBP) averages, respectively, were above
the 95th percentile for their sex, age, and height.15
We categorized all subjects who were not on antihyperten-
sive medication using the combination of clinic BP measure-
ments and ABPM into 4 categories: sustained hypertensives
(screen positive and conﬁrmed hypertensive on ABPM); white
coat hypertensives (screen positive, not conﬁrmed hyperten-
sive on ABPM); masked hypertensives (screen negative,
conﬁrmed hypertensive on ABPM); or normotensives (screen
negative, not conﬁrmed hypertensive on ABPM).23
Dipping status was deﬁned using ABPM data only, using
day and night periods as deﬁned above. Subjects were
classiﬁed using the following 4 categories, based on the
night/day ratio of mean SBP and/or DBP: rising or absence of
dipping (ratio ≥1.0); mild dipping (0.9< ratio ≤1.0); dipping
(0.8< ratio ≤0.9); and extreme dipping (ratio ≤0.8).24
Laboratory Procedures
We collected 10 mL of blood from participants for full blood
count, determination of a+thalassemia genotype, and serum
electrolytes. After performing automated full blood counts
using an ACT 5 machine, whole blood samples were frozen at
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80°C and then transported to the KEMRI-Wellcome Trust
Research Programme laboratories in Kiliﬁ, Kenya, for geno-
typing. DNA was extracted retrospectively from frozen
samples by use of Qiagen DNA blood mini-kits (Qiagen,
Crawley, UK) and typed for the common African 3.7-kb HBA
deletion by polymerase chain reaction.25
Serum and urine samples collected from participants were
frozen at 80°C within 4 hours of collection and later
transported to Kiliﬁ, Kenya, for subsequent analysis. We
determined sodium and potassium, urea, and creatinine levels
in these samples using ion electrophoresis and the Jaffe
method, respectively.26 We additionally determined albumin
levels in urine samples by immunoturbidometry using aQuantex
microalbumin kit.
Estimated glomerular ﬁltration rate (eGFR) was calculated
using the Schwarz formula.27
Statistical Analysis
Based on an expected minimum prevalence for heterozygous
a+thalassemia (a/aa) of 20% in the ethnic groups we were
studying, an SBP SD of 15 mm Hg, and 30% attrition
because of poor-quality ABPM data, we estimated that a total
of 472 participants would provide 80% power to detect one
third of an SD (5 mm Hg) difference in 24-hour SBP between
a/aa and aa/aa individuals.
Summary statistics that were computed included means,
medians, and proportions as appropriate. We used the
Student t test to separately compare continuous variables in
a/aa and a/a to aa/aa individuals. The chi-squared
test was used to compare categorical variables. We con-
ducted multiple regression analyses to determine whether
inclusion of a+thalassemia genotype predicted 24-hour SBP
and/or DBP. Age, sex, BMI, eGFR, and PWV, which have all
been previously associated with BP, were included as
covariates in the base model. To determine whether a+tha-
lassemia genotype inﬂuenced 24-hour BP, we added it to the
base model and used the likelihood ratio test to determine
whether it improved the ﬁt. We additionally tested for
interaction with the sickle cell trait, because it has previously
been associated with cardiovascular and renal events.28–31 All
analyses were conducted using Stata software (version 12;
StataCorp LP, College Station, TX).
The Kenya Medical Research Institute’s Ethical Review
Committee approved the study. Written informed consent was
obtained from parents of study participants. Participating
children also provided written assent.
Results
Of the 938 subjects invited to participate in the study, 686
completed enrollment (Figure 1). None of the participants
were previously aware of their a+thalassemia status. The 252
adolescents that were not recruited into the study were
0.6 years (95% CI, 0.3–0.9) older than study participants, but
with a similar sex distribution (53% female) to those that
participated in the study. Data on a+thalassemia genotype
were available for 664 (97%) participants. Two hundred forty-
six (37%) were heterozygous (a/aa) and 49 (7%) were
homozygous (a/a) for a+thalassemia whereas the remain-
ing 369 (56%) subjects were normal (aa/aa). One hundred
three (15.5%) of the adolescents were carriers of the sickle
cell trait, distributed equally among the a+thalassemia
genotypic groups (14%, 17%, and 16% in aa/aa, a/aa,
and a/a subjects, respectively; P=0.652). After excluding
those with poor-quality ABPM data, 623 (94%) subjects
provided quality data for the analysis (Figure 1). A slightly
lower proportion of a/aa participants had complete ABPM
data (91%) compared with aa/aa (95%) and a/a subjects
(97%). Mean clinic BPSD among all participants was
9811 mm Hg SBP and 648 mm Hg DBP. Mean 24-hour
BPSD for all participants was 11712 mm Hg SBP and
648 mm Hg DBP. Mean 24-hour pulse wave velocity
(PWV)SD was 70.8 ms1. The study had >98% power to
detect one third of an SD difference in either SBP or DBP
(4 and 2.7 mm Hg, respectively) between aa/aa individuals
and those with a/aa and a 0.3 ms1 (one third of an SD)
difference in PWV between aa/aa individuals and those with
a/aa. The study had >90% power to detect differences
equivalent to 0.5 SDs in BP and PWV between aa/aa and
a/a individuals.
Figure 1. Study ﬂow chart.
DOI: 10.1161/JAHA.117.005613 Journal of the American Heart Association 3
Blood Pressure in Alpha Thalassemia Etyang et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on M
arch 5, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Table 1 displays the characteristics of study participants
according to a+thalassemia genotype. As expected, hemoglo-
bin concentrations were signiﬁcantly lower in a/a than in
a/aa or aa/aa subjects. BMI was lower in a/aa than in
aa/aa individuals (18.2 versus 19.2; P=0.0004) whereas
MUAC was signiﬁcantly smaller in a/aa compared with
aa/aa individuals. There were no statistically signiﬁcant
differences in prevalence of masked hypertension, white coat
hypertension, or in the pattern of nondipping BP by
a+thalassemia genotype. PWV was also similar in all 3 groups.
Figure 2 displays mean 24-hour, daytime, and nighttime
BPs in study participants by a+thalassemia genotype. All
measures were similar for all 3 groups.
The results of regression analyses are displayed in Table 2.
Age, sex, BMI, eGFR, and PWV were all independent predictors
of 24-hour SBP whereas PWV was the only independent
predictor of 24-hour DBP. Twenty-four-hour BP values were
not associated with a+thalassemia genotype in any of our
regression models, and its inclusion in the ﬁnal model did not
improve the ﬁt (likelihood ratio test, P=0.96 for SBP and
P=0.75 for DBP). Adjustment for proxy markers of hemolysis
(hemoglobin level, mean corpuscular volume, and mean
corpuscular hemoglobin concentration) made no difference
to the results, and neither did the inclusion of interaction
terms for sex and sickle cell trait status.
Discussion
The a+thalassemias are the most common human monogenic
disorders.1 Demonstration of altered BP in individuals with
any of the mutations would be of immense importance, given
that it would improve the understanding of BP regulation and
aid the development of new drugs. In this detailed study of BP
phenotypes and arterial stiffness among adolescents, we did
not ﬁnd any differences between those with and without
a+thalassemia. Because the exposure measurement was a
genetic trait acquired at conception and the participants were
ascertained to have remained in the same malaria-free
environment since birth, we believe that this study suggests
that a direct effect of a+thalassemia on BP and indices of
arterial stiffness within the ﬁrst 11 to 17 years of life is highly
improbable.
Table 1. Characteristics of Study Participants (N=623)
Characteristic
Normal (aa/aa)
N=353
Heterozygous (a/aa)
N=223
Homozygous (a/a)
N=47 P Value* P Value†
Age, y 13.4 (2.2) 13.0 (2.2) 13.4 (2.4) 0.0289 0.9
Female, N (%) 187 (53) 132 (59) 28 (58) 0.3 0.3
BMI, kg/m2 19.2 (3.2) 18.3 (2.6) 19.2 (3.6) 0.0004 0.9
MUAC, cm 23.7 (3.9) 22.7 (3.1) 23.2 (4) 0.0007 0.4
Hemoglobin, mg/dL 13.5 (1.5) 13.1 (1.4) 12.2 (1.6) 0.0004 <0.0001
Mean cell volume, fL 84 (5) 79 (5) 70 (5) <0.0001 <0.0001
Mean corpuscular hemoglobin concentration, g/dL 32 (2) 31 (2) 31 (2) 0.0003 <0.0001
Socioeconomic status (MDPI score) 2.0 (1.2) 2.3 (1.4) 2.4 (1.1) 0.0126 0.3
24-hour SBP, mm Hg 118 (12) 117 (11) 118 (11) 0.1 1.0
24-hour DBP, mm Hg 64 (8) 63 (7) 65 (8) 0.1 0.6
24-hour pulse wave velocity, ms1 7.0 (0.8) 7.0 (0.8) 7.0 (0.7) 0.2 0.5
Systolic morning BP surge, mm Hg 9 (12) 8 (12) 11 (10) 0. 6 0.2
Augmentation index, % 17 (6) 17 (6) 16 (5) 0.8 0.4
White coat hypertension, N (%) 15 (4) 8 (4) 3 (6) 0.2 0.4
Masked hypertension, N (%) 25 (7) 21 (9) 7 (15) 1.0 0.073
Nondipping BP pattern 24 (7) 7 (3) 2 (4) 0.1 0.9
eGFR, mL/min per 1.73 m2 109 (15) 111 (14) 110 (13) 0.1 0.6
Log10UACr 0.4 (0.6) 0.3 (0.7) 0.2 (1) 0.4 0.1
Urine sodium, mmol/L 137 (82) 130 (53) 128 (51) 0.3 0.5
Urine potassium, mmol/L 48 (32) 46 (29) 42 (20) 0.4 0.2
Data are mean (SD), unless speciﬁed. BP indicates blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular ﬁltration rate; MDPI, multidimensional poverty index; MUAC,
mid-upper-arm circumference; systolic blood pressure; UACr, urine albumin-to-creatinine ratio.
P values are for comparisons between normal and heterozygous* and normal and homozygous†.
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On the face of it, our results do not align with ﬁndings from
other studies that have suggested the possibility that
expression of Hba might affect BP.6,8,11 These studies were
either done in vitro or in mouse models with very limited
sample sizes (N=6).8 The review by Butcher et al11 that
reported an association between a+thalassemia and moderate
hypotension did not refer to a primary publication. It is
possible that the lower BPs observed in subjects with
a+thalassemia who are relatively protected from malaria
could actually be a conﬁrmation that malaria raises BP as we
have previously hypothesized.18 An alternative explanation for
similar BP despite the presence of Hba deletions could be
attributed to canalization, a phenomenon where individuals or
organisms develop the same phenotype despite differences in
their genetic makeup.32 Reddy et al33 have shown that
infusion of HbH (levels of which are elevated in a+tha-
lassemia) into rats results in elevation of BP as a result of HbH
having higher afﬁnity for NO than HbA.34 It is therefore
possible that the BP-lowering effect of a+thalassemia is
cancelled out by the opposing effect of elevated levels of
HbH. This would also suggest that recently developed
molecules that mimic alpha globin35 may have reduced
effectiveness in individuals with a+thalassemia. Additional
studies are needed to fully understand these seemingly
contrasting effects and generate a uniﬁed model incorporat-
ing both environmental conditions and genetic effects.
A major strength of this study was the use of ABPM, which
is considered the reference standard for BP measurement in
children.15 The study was well powered to detect very small
differences in BP and PWV. Although it could be argued that
PWV is predominantly a measure of large conduit arteries,
which do not express Hb alpha, it integrates the interface
between small arteries and resistance vessels—as, for
instance, in diabetes mellitus where small vessel damage is
as frequent as large.36 An additional strength of the study is
that we used health and demographic surveillance system
(HDSS) records that were prospectively collected in order to
ascertain residence in a nonmalaria zone, there being no
better method of doing this in sub-Saharan Africa.
One limitation of this study was the limited age range of
subjects recruited, necessitated by the fact that there were no
long-term residency records for older individuals. Most HDSSs
in sub-Saharan Africa were established in the late 1990s to
early 2000s.37 Recruiting older individuals would have com-
promised data on residency status in childhood, the period
when malaria risk is highest. Although BP differences are
likely to be larger at older ages, it is known that differences in
adult BP emerge in childhood38,39 and that childhood BP
levels are predictive of adult BP.40 The absence of even a
small difference in carefully measured BP and arterial stiffness
in our study of adolescents therefore suggests that it is very
unlikely such differences would emerge in future.
A second limitation of the study is the fact that we did not
measure levels of markers of hemolysis, such as HbH and
haptoglobin, and other potential compensatory mechanisms,
such as (decreased) eNOS or guanylyl cyclase expression, or
increased catecholamine levels among study participants.
This would have helped to either conﬁrm or refute the
Figure 2. Twenty-four hour ABPM measures by alpha tha-
lassemia status. Data are mean and 95% CIs. ABPM indicates
ambulatory blood pressure monitoring; BP, blood pressure.
Table 2. Regression Analyses Investigating Possible Effect of Thalassemia Status on 24-Hour Systolic and Diastolic BP
24-Hour SBP 24-Hour DBP
b, 95% CI P Value b, 95% CI P Value
Age, y 0.6 (0.1–1.2) 0.021 0.03 (0.3 to 0.4) 0.9
Male sex 2.6 (0.7–4.5) 0.009 0.2 (1.1 to 1.4) 0.9
BMI, kg/m2 0.6 (0.2–1) 0.001 0.2 (0.1 to 0.4) 0.2
PWV, ms1 2.8 (1.6–4.1) <0.001 2.7 (1.9–3.6) <0.001
eGFR, mL/min per 1.73 m2 0.1 (0.03–0.2) 0.006 0.02 (0.02 to 0.06) 0.4
a+thalassemia genotype 0.04 (1.4 to 1.5) 1.0 0.1 (0.8 to 1.1) 0.8
Likelihood ratio test for models including versus excluding a+thalassemia genotype P=1.0 for SBP and P=0.8 for DBP. BP indicates blood pressure; eGFR, estimated glomerular ﬁltration
rate; PWV, pulse wave velocity.
DOI: 10.1161/JAHA.117.005613 Journal of the American Heart Association 5
Blood Pressure in Alpha Thalassemia Etyang et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on M
arch 5, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
possibility of canalization explaining the lack of an effect of
a+thalassemia on BP levels. This could form the basis of
future studies to better understand the seemingly contrasting
ﬁndings of experimental and human studies.
It is also important to note that no studies have to date
established whether alpha hemoglobin is expressed in
endothelial cells of human subjects and whether the 3.7-kb
deletion, the most common defect causing a+thalassemia1 in
humans, also results in reduced endothelial expression of
alpha hemoglobin. Additional studies are required to deter-
mine whether there is endothelial expression of alpha
hemoglobin in humans, whether the 3.7-kb deletion results
in reduced endothelial a globin expression, and whether other
defects resulting in a+thalassemia present with the same
vascular phenotype that we observed.
In summary, we have demonstrated that there are no
differences in BP and arterial stiffness based on a+tha-
lassemia genotype in Kenyan adolescents living within a non-
malaria-endemic environment. Additional studies are required
to explain the apparent contradictory results of experimental
studies.
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